ReviewLife sciences2020
Coronaviruses pandemics: Can neutralizing antibodies help?
Review in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Vitamin D as an Adjuvant Immune Enhancer to SARS-Cov-2 Vaccine.Current microbiology · 2025Article
- Individual Immune Response to SARS-CoV-2 Infection-The Role of Seasonal Coronaviruses and Human Leukocyte Antigen.Biology · 2023Article
- Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.Journal of nanobiotechnology · 2023Review
- Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines.Human immunology · 2022Review
- Mapping COVID-19 related research from Vietnam: a scoping review.Journal of preventive medicine and hygiene · 2022Article
- Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.Frontiers in medicine · 2022Article
- Various vaccine platforms in the field of COVID-19.Beni-Suef University journal of basic and applied sciences · 2022Review
- Coronaviruses construct an interconnection way with ERAD and autophagy.Future microbiology · 2021Review
- Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.ACS pharmacology & translational science · 2021Article
- Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing.Transfusion · 2021Article
- COVID-19 vaccines: The status and perspectives in delivery points of view.Advanced drug delivery reviews · 2021Review
- A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.Cellular & molecular immunology · 2021Article
- SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.Communications biology · 2021Article
- Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Development and implementation of a COVID-19 convalescent plasma program in a middle-income economy.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the first time in Homo sapiens history, possibly, most of human activities is stopped by coronavirus disease 2019 (COVID-19). Nearly eight billion people of this world are facing a great challenge, maybe not "to be or not to be" yet, but unpredictable. What happens to other major pandemics in the past, and how human beings went through these hurdles? The human body is equipped with the immune system that can recognize, respond and fight against pathogens such as viruses. Following the innate response, immune system processes the adaptive response by which each pathogen is encoded and recorded in memory system. The humoral reaction containing cytokines and antibodies is expected to activate when the pathogens come back. Exploiting this nature of body protection, neutralizing antibodies have been investigated. Learning from past, in parallel to SARS-CoV-2, other coronaviruses SARS-CoV and MERS-CoV who caused previous pandemics, are recalled in this review. We here propose insights of origin and characteristics and perspective for the future of antibodies development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.